106 related articles for article (PubMed ID: 16816566)
1. Out-of-pocket costs of HAART limit HIV treatment responses in Botswana's private sector.
Bisson GP; Frank I; Gross R; Lo Re V; Strom JB; Wang X; Mogorosi M; Gaolathe T; Ndwapi N; Friedman H; Strom BL; Dickinson D
AIDS; 2006 Jun; 20(9):1333-6. PubMed ID: 16816566
[TBL] [Abstract][Full Text] [Related]
2. Public-private partnerships and antiretroviral drugs for HIV/AIDS: lessons from Botswana.
Ramiah I; Reich MR
Health Aff (Millwood); 2005; 24(2):545-51. PubMed ID: 15757942
[TBL] [Abstract][Full Text] [Related]
3. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
[TBL] [Abstract][Full Text] [Related]
4. The cost of antiretroviral drugs and influence on prescribing policies.
Jones R; Gazzard B
Int J STD AIDS; 2006 Aug; 17(8):499-506. PubMed ID: 16925892
[TBL] [Abstract][Full Text] [Related]
5. Antiretroviral therapy improves cognitive impairment in HIV+ individuals in sub-Saharan Africa.
Sacktor N; Nakasujja N; Skolasky R; Robertson K; Wong M; Musisi S; Ronald A; Katabira E
Neurology; 2006 Jul; 67(2):311-4. PubMed ID: 16864825
[TBL] [Abstract][Full Text] [Related]
6. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review.
Barth RE; van der Loeff MF; Schuurman R; Hoepelman AI; Wensing AM
Lancet Infect Dis; 2010 Mar; 10(3):155-66. PubMed ID: 20185094
[TBL] [Abstract][Full Text] [Related]
7. Immune activation despite suppressive highly active antiretroviral therapy is associated with higher risk of viral blips in HIV-1-infected individuals.
Zoufaly A; Kiepe JG; Hertling S; Hüfner A; Degen O; Feldt T; Schmiedel S; Kurowski M; van Lunzen J
HIV Med; 2014 Sep; 15(8):449-57. PubMed ID: 24580846
[TBL] [Abstract][Full Text] [Related]
8. Antiretroviral failure despite high levels of adherence: discordant adherence-response relationship in Botswana.
Bisson GP; Rowh A; Weinstein R; Gaolathe T; Frank I; Gross R
J Acquir Immune Defic Syndr; 2008 Sep; 49(1):107-10. PubMed ID: 18667926
[TBL] [Abstract][Full Text] [Related]
9. Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program.
Bussmann H; Wester CW; Ndwapi N; Grundmann N; Gaolathe T; Puvimanasinghe J; Avalos A; Mine M; Seipone K; Essex M; Degruttola V; Marlink RG
AIDS; 2008 Nov; 22(17):2303-11. PubMed ID: 18981769
[TBL] [Abstract][Full Text] [Related]
10. Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy.
Hulgan T; Shepherd BE; Raffanti SP; Fusco JS; Beckerman R; Barkanic G; Sterling TR
J Infect Dis; 2007 Feb; 195(3):425-31. PubMed ID: 17205482
[TBL] [Abstract][Full Text] [Related]
11. Costs and benefits of HAART for patients with HIV in a public hospital in Mexico.
Aracena-Genao B; Navarro JO; Lamadrid-Figueroa H; Forsythe S; Trejo-Valdivia B
AIDS; 2008 Jul; 22 Suppl 1():S141-8. PubMed ID: 18664946
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of the Botswana national HIV/AIDS treatment programme from 2002 to 2010: a longitudinal analysis.
Farahani M; Vable A; Lebelonyane R; Seipone K; Anderson M; Avalos A; Chadborn T; Tilahun H; Roumis D; Moeti T; Musuka G; Busang L; Gaolathe T; Malefho KC; Marlink R
Lancet Glob Health; 2014 Jan; 2(1):e44-50. PubMed ID: 25104635
[TBL] [Abstract][Full Text] [Related]
13. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine.
Mocroft A; Devereux H; Kinloch-de-Loes S; Wilson D; Madge S; Youle M; Tyrer M; Loveday C; Phillips AN; Johnson MA
AIDS; 2000 Jul; 14(11):1545-52. PubMed ID: 10983641
[TBL] [Abstract][Full Text] [Related]
14. Declining risk of triple-class antiretroviral drug failure in Danish HIV-infected individuals.
Lohse N; Obel N; Kronborg G; Laursen A; Pedersen C; Larsen CS; Kvinesdal B; Sørensen HT; Gerstoft J
AIDS; 2005 May; 19(8):815-22. PubMed ID: 15867496
[TBL] [Abstract][Full Text] [Related]
15. Zidovudine- versus Tenofovir-Based Antiretroviral Therapy for the Initial Treatment of HIV Infection in the Ethnic Minority Region of Liangshan Prefecture, Sichuan Province, China.
Cheung CP; Lai WH; Shuter J
J Int Assoc Provid AIDS Care; 2017; 16(2):189-193. PubMed ID: 28043197
[TBL] [Abstract][Full Text] [Related]
16. Highly active antiretroviral therapy started during pregnancy or postpartum suppresses HIV-1 RNA, but not DNA, in breast milk.
Shapiro RL; Ndung'u T; Lockman S; Smeaton LM; Thior I; Wester C; Stevens L; Sebetso G; Gaseitsiwe S; Peter T; Essex M
J Infect Dis; 2005 Sep; 192(5):713-9. PubMed ID: 16088820
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of highly active antiretroviral therapy in South Africa.
Badri M; Maartens G; Mandalia S; Bekker LG; Penrod JR; Platt RW; Wood R; Beck EJ
PLoS Med; 2006 Jan; 3(1):e4. PubMed ID: 16318413
[TBL] [Abstract][Full Text] [Related]
18. Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication.
Alatrakchi N; Duvivier C; Costagliola D; Samri A; Marcelin AG; Kamkamidze G; Astriti M; Agher R; Calvez V; Autran B; Katlama C
AIDS; 2005 Jan; 19(1):25-33. PubMed ID: 15627030
[TBL] [Abstract][Full Text] [Related]
19. Undisclosed antiretroviral drug use in Botswana: implication for national estimates.
Moyo S; Gaseitsiwe S; Powis KM; Pretorius Holme M; Mohammed T; Zahralban-Steele M; Yankinde EK; Maphorisa C; Abrams W; Lebelonyane R; Manyake K; Sekoto T; Mmalane M; Gaolathe T; Wirth KE; Makhema J; Lockman S; Clarke W; Essex M; Novitsky V
AIDS; 2018 Jul; 32(11):1543-1546. PubMed ID: 29762166
[TBL] [Abstract][Full Text] [Related]
20. [Non-antiretroviral drugs uses among HIV-infected persons receiving antiretroviral therapy in Senegal: Costs and factors associated with prescription].
Diouf A; Youbong TJ; Maynart M; Ndoye M; Diéye FL; Ndiaye NA; Koita-Fall MB; Ndiaye B; Seydi M
Rev Epidemiol Sante Publique; 2017 Aug; 65(4):295-300. PubMed ID: 28502580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
